NLTX Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics, Inc. is a biopharmaceutical company, which engages in the design of de novo protein therapeutics to address significant unmet medical needs in oncology, inflammation, and autoimmunity. Its products include NL-201-- a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin-2. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.

$7.03  +0.18 (2.63%)
As of 10/19/2021 15:59:58 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—Specialty &
Index country:  USA
Country of incorporation:  USA
IPO date:  08/12/2019
Outstanding shares:  42,425,071
Average volume:  90,849
Market cap:   $306,309,013
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    64049K104
ISIN:        US64049K1043
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   2.88
PS ratio:   0.00
Return on equity:   -26.92%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy